GCP
TVTX icon

GSA Capital Partners’s Travere Therapeutics TVTX Stock Holding History

GSA Capital Partners’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$528K Buy
+9,292
New +$412K 0.03% 968
2025
Q3 		– Sell
-88,195
Closed -$1.3M – 2108
2025
Q2 		$1.3M Buy
+88,195
New +$1.46M 0.09% 306
2025
Q1 		– Sell
-74,356
Closed -$1.29M – 2087
2024
Q4 		$1.29M Buy
+74,356
New +$1.32M 0.1% 250
2024
Q2 		– Sell
-58,601
Closed -$452K – 2033
2024
Q1 		$452K Buy
+58,601
New +$494K 0.04% 948
2021
Q1 		– Sell
-41,806
Closed -$1.14M – 1503
2020
Q4 		$1.14M Buy
+41,806
New +$976K 0.19% 100
2018
Q4 		– Sell
-11,600
Closed -$333K – 1741
2018
Q3 		$333K Buy
+11,600
New +$332K 0.02% 1273
2018
Q1 		– Sell
-28,100
Closed -$592K – 1834
2017
Q4 		$592K Buy
28,100
+16,400
+140% +$375K 0.04% 857
2017
Q3 		$291K Sell
11,700
-2,700
-19% -$59.5K 0.02% 1274
2017
Q2 		$279K Buy
+14,400
New +$261K 0.02% 1323
2017
Q1 		– Sell
-33,245
Closed -$629K – 1999
2016
Q4 		$629K Buy
33,245
+14,345
+76% +$293K 0.04% 847
2016
Q3 		$423K Sell
18,900
-27,609
-59% -$526K 0.02% 1152
2016
Q2 		$828K Buy
46,509
+18,920
+69% +$306K 0.05% 753
2016
Q1 		$377K Buy
+27,589
New +$419K 0.02% 1176
2015
Q4 		– Sell
-48,990
Closed -$993K – 1971
2015
Q3 		$993K Buy
48,990
+39,470
+415% +$1.17M 0.05% 635
2015
Q2 		$316K Buy
+9,520
New +$261K 0.01% 1590
2014
Q4 		– Sell
-30,444
Closed -$275K – 1902
2014
Q3 		$275K Buy
+30,444
New +$358K 0.01% 1318

Other funds holding TVTX

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

GSA Capital Partners's TVTX Position: Q2 2026 in Review

GSA Capital Partners opened a new position in Travere Therapeutics (TVTX) in Q2 2026: 9,292 shares worth $528K. The stake represents 0.03% of the portfolio and ranks #968 among its holdings. This is a return to the name: GSA Capital Partners previously reported a position in TVTX as recently as Q2 2025.

GSA Capital Partners first reported a position in TVTX in Q3 2014 and has held it in 16 quarters since. The position peaked at $1.3M in Q2 2025. 321 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • GSA Capital Partners held 9,292 shares of Travere Therapeutics worth $528K as of Q2 2026.
  • Travere Therapeutics was a new GSA Capital Partners position in Q2 2026.
  • Travere Therapeutics made up 0.03% of GSA Capital Partners's portfolio in Q2 2026, its #968 holding.
  • GSA Capital Partners first reported a position in Travere Therapeutics in Q3 2014 and has held it in 16 quarters since.
  • GSA Capital Partners's Travere Therapeutics position peaked at $1.3M in Q2 2025.
  • 321 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.